- Home
- / Amplia Therapeutics
Amplia Therapeutics
Stock Price
$0.2
2024-10-18
Market Capitalization
$42.6 M
2024-10-18
Amplia Therapeutics Summary
Company Summary
- Overview
- Amplia Therapeutics is a pharmaceutical company developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. It focuses on pancreatic and ovarian cancer as well as idiopathic pulmonary fibrosis (IPF).
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- Melbourne, AU | view all locations
- Cybersecurity rating
Table of Contents
Key People
Jeff Carter, Chief Financial Officer
LocationsView all
1 location detected
Melbourne, VIC HQ
Australia
Level 21/90 Collins St
Amplia Therapeutics Financials
Summary Financials
- Gross profit (H1, 2026)
- $2.6M
- Net income (H1, 2026)
- ($4.2M)
- Cash (H1, 2026)
- $29.2M
- EBIT (H1, 2026)
- ($4.4M)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026